Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

186 DOBUTAMINE
DOBUTAMINE
Trade names: Cardiject; Dobril; Dobuject; Dobutamin;
Dobutrex (Lilly); Inotrex; Oxiken; Tobrex
Indications: Cardiac surgery, heart failure
Category: Adrenergic beta-receptor agonist; Catecholamine;
Inotropic sympathomimetic
Half-life: 2 minutes
Clinically important, potentially hazardous interactions
with: furazolidone
Reactions
Skin
Cellulitis
(1994): Cernek PK, Ann Pharmacother 28, 964
Erythema
(1991): Wu CC+, Chest 99, 1547
Necrosis
Pruritus
(1991): Wu CC+, Chest 99, 1547
(1986): McCauley CS+, AnnInternMed105, 966 (scalp)
Other
Hypersensitivity
(1991): Wu CC+, Chest 99, 1547
Injection-site pain
Injection-site phlebitis
Phlebitis
DOCETAXEL
Trade name: Taxotere (Sanofi-Aventis)
Indications: Metastatic breast cancer
Category: Taxane
Half-life: 11–18 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, aprepitant, prednisone
Reactions
Skin
Allergic reactions (sic)
(2001): Talla M+, Therapie 56(5), 632
Angioedema
Edema (1–20%)
(2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 393 (with
cyclophosphamide) (25%)
(2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 453 (100%)
(2004): Furugen Y+, Gan To Kagaku Ryoho 31(8), 1205 (30%)
(with carboplatin)
(2003): Qin YK+, Ai Zheng 22(4), 415
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(1996): Edmonson JH+, Am J Clin Oncon 19, 574
(1993): Schrijvers D+, Ann Oncol 4, 610 (20%)
Erythema (0.9%)
(2002): Hirai K+, Gynecol Obstet Invest 53(2), 118
(1995): Cortes JE+, J Clin Oncol 13, 2643
Exanthems
(1995): Cortes JE+, J Clin Oncol 13, 2643
(1995): Zimmerman GC+, Arch Dermatol 131, 202
Facial erythema
(2004): Katoh M+, JDermatol31(5), 403
Fixed eruption (erythematous plaque)
(2000): Chu CY+, Br J Dermatol 142, 808
Hand–foot syndrome
(2006): Kara IO+, Breast 15(3), 414 (with capecitabine)
(2005): Levy C+, Cancer Treat Rev 31 Suppl 4, S17 (with
capecitabine)
(2005): Ramanathan RK+, Cancer Chemother Pharmacol
55(4), 354 (with capecitabine)
(2004): Katoh M+, JDermatol31(5), 403
(2004): Lebowitz PF+, Clin Cancer Res 10(20), 6764 (with
capecitabine)
(2004): Mackey JR+, Clin Breast Cancer 5(4), 287 (30%) (with
capecitabine)
(2004): Park YH+, Br J Cancer 90(7), 1329 (with capecitabine)
(2004): Pavlick AC+, Anticancer Drugs 15(2), 119 (with
doxorubicin)
(2003): Han JY+, Cancer 98(9), 1918 (33%) (with capecitabine)
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (2 cases)
(2002): O’Shaughnessy J+, J Clin Oncol 20(12), 2812 (with
capecitabine)
(2000): Chu CY+, Br J Dermatol 142(4), 808
(1995): Zimmerman GC+, Arch Dermatol 131, 202
(1994): Zimmerman GC+, J Natl Cancer Inst 86, 557
(1993): Vukelja SJ+, J Natl Cancer Inst 85, 1432
Lupus erythematosus
(2004): Chen M+, J Rheumatol 31(4), 818 (4 cases) (subacute)
Peripheral edema
(2002): Koukourakis MI+, Anticancer Res 22(4), 2491
(1998): Hainsworth JD+, J Clin Oncol 16(6), 2164
(1995): Zimmerman GC+, Arch Dermatol 131, 202
Photo-recall
(2005): Kandemir EG+, Swiss Med Wkly 135(1-2), 34
(2002): Magne N+, Cancer Radiother 6(5), 281 (2 cases)
(2002): Morkas M+, J Clin Oncol 20(3), 867
(2002): Piroth MD+, Onkologie 25(5), 438
(2001): Giesel BU+, Strahlenther Onkol 177(9), 487
(1995): Zimmerman GC+, Arch Dermatol 101, 202
Photosensitivity
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(1995): Zimmerman GC+, Arch Dermatol 131, 202
Pigmentation
(2005): Aydogan I+, J Eur Acad Dermatol Venereol 19(3), 345
(supravenous)
Pruritus
(1995): Cortes JE+, J Clin Oncol 13, 2643
Radiodermatitis
(2005): Borgia F+, Br J Dermatol 153(3), 674
Rash (sic) (0.9%)
(1996): Edmonson JH+, Am J Clin Oncon 19, 574
Recall reaction
(2005): Chu CY+, Br J Dermatol 153(2), 441
Scleroderma
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(2001): Hassett G+, Clin Exp Rheumatol 19(2), 197
(2000): Cleveland MG+, Cancer 88(5), 1078
(1995): Battafarano DF+, Cancer 76, 110
Seborrheic keratoses
(2001): Chu CY+, Acta Derm Venereol 81(4), 316
Squamous syringometaplasia
(2002): Karam A+, Br J Dermatol 146(3), 524
Toxic epidermal necrolysis
(2002): Dourakis SP+, J Clin Oncol 20(13), 3030
Toxicity (sic)
(2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 393 (with
cyclophosphamide) (13%)
(2007): Tinker AV+, Gynecol Oncol 104(3), 647 (3%)
(2003): Fracasso PM+, Cancer 98(3), 610
Urticaria
(2005): Feldweg AM+, Gynecol Oncol 96(3), 824
Xerosis